| Year |
Citation |
Score |
| 2015 |
Rocha EM, Smith GA, Park E, Cao H, Brown E, Hallett P, Isacson O. Progressive decline of glucocerebrosidase in aging and Parkinson's disease. Annals of Clinical and Translational Neurology. 2: 433-8. PMID 25909088 DOI: 10.1002/Acn3.177 |
0.328 |
|
| 2015 |
Smith GA, Rocha EM, Rooney T, Barneoud P, McLean JR, Beagan J, Osborn T, Coimbra M, Luo Y, Hallett PJ, Isacson O. A Nurr1 agonist causes neuroprotection in a Parkinson's disease lesion model primed with the toll-like receptor 3 dsRNA inflammatory stimulant poly(I:C). Plos One. 10: e0121072. PMID 25815475 DOI: 10.1371/Journal.Pone.0121072 |
0.344 |
|
| 2010 |
Silverdale MA, Kobylecki C, Hallett PJ, Li Q, Dunah AW, Ravenscroft P, Bezard E, Brotchie JM. Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate. Synapse (New York, N.Y.). 64: 177-80. PMID 19852073 DOI: 10.1002/syn.20739 |
0.67 |
|
| 2009 |
Zhang J, Xu TX, Hallett PJ, Watanabe M, Grant SG, Isacson O, Yao WD. PSD-95 uncouples dopamine-glutamate interaction in the D1/PSD-95/NMDA receptor complex. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 2948-60. PMID 19261890 DOI: 10.1523/Jneurosci.4424-08.2009 |
0.507 |
|
| 2008 |
Hallett PJ, Collins TL, Standaert DG, Dunah AW. Biochemical fractionation of brain tissue for studies of receptor distribution and trafficking. Current Protocols in Neuroscience / Editorial Board, Jacqueline N. Crawley ... [Et Al.]. Unit 1.16. PMID 18428670 DOI: 10.1002/0471142301.ns0116s42 |
0.601 |
|
| 2008 |
Nicholas AP, Lubin FD, Hallett PJ, Vattem P, Ravenscroft P, Bezard E, Zhou S, Fox SH, Brotchie JM, Sweatt JD, Standaert DG. Striatal histone modifications in models of levodopa-induced dyskinesia. Journal of Neurochemistry. 106: 486-94. PMID 18410512 DOI: 10.1111/j.1471-4159.2008.05417.x |
0.454 |
|
| 2008 |
Mendez I, Viñuela A, Astradsson A, Mukhida K, Hallett P, Robertson H, Tierney T, Holness R, Dagher A, Trojanowski JQ, Isacson O. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nature Medicine. 14: 507-9. PMID 18391961 DOI: 10.1038/Nm1752 |
0.304 |
|
| 2007 |
Zhang J, Vinuela A, Neely MH, Hallett PJ, Grant SG, Miller GM, Isacson O, Caron MG, Yao WD. Inhibition of the dopamine D1 receptor signaling by PSD-95. The Journal of Biological Chemistry. 282: 15778-89. PMID 17369255 DOI: 10.1074/Jbc.M611485200 |
0.392 |
|
| 2007 |
Hallett PJ, Brotchie JM. Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia. Movement Disorders : Official Journal of the Movement Disorder Society. 22: 28-40. PMID 17089424 DOI: 10.1002/mds.21163 |
0.338 |
|
| 2006 |
Hallett PJ, Spoelgen R, Hyman BT, Standaert DG, Dunah AW. Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 26: 4690-700. PMID 16641250 DOI: 10.1523/Jneurosci.0792-06.2006 |
0.663 |
|
| 2005 |
Hallett PJ, Dunah AW, Ravenscroft P, Zhou S, Bezard E, Crossman AR, Brotchie JM, Standaert DG. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology. 48: 503-16. PMID 15755478 DOI: 10.1016/j.neuropharm.2004.11.008 |
0.666 |
|
| 2004 |
Hallett PJ, Standaert DG. Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacology & Therapeutics. 102: 155-74. PMID 15163596 DOI: 10.1016/j.pharmthera.2004.04.001 |
0.673 |
|
| Show low-probability matches. |